The FDA has approved delafloxacin (Baxdela – Melinta), an anionic fluoroquinolone antibiotic, for oral and parenteral treatment of adults with acute bacterial skin and skin structure infections (ABSSSIs), including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is the first fluoroquinolone to be approved for treatment of MRSA.

ABSSSIs — The FDA's definition of an ABSSSI includes cellulitis/erysipelas, major cutaneous abscess, wound infection, or burn infection, with a minimum lesion size of 75 cm² and symptoms of systemic infection. Patients with chronic infections such as diabetic foot and decubitus ulcer infections, human and animal bites, and necrotizing fasciitis are excluded from ABSSSI trials.1

STANDARD TREATMENT — In many parts of the US, purulent skin and soft-tissue infections are now ... more      

Would you like to read the rest of this article?  Gain access below.